Catalyst

Slingshot members are tracking this event:

AstraZeneca (AZN) Announces Phase 3 Results for Bydureon + Farxiga in Treatment of Type 2 Diabetes

Source Link:
https://www.astrazeneca.com/media-centre/press-releases/2016/phase-III-combination-trial-of-bydureon-and-forxiga-shows-significant-benefits-in-patients-with-type-2-diabetes-1609201611.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Bydureon, Forxiga, Phase Iii Results
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.